Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$13.88
-2.3%
$12.14
$10.45
$21.69
$4.91B0.62724,953 shs388,566 shs
Glaukos Corporation stock logo
GKOS
Glaukos
$103.68
-2.7%
$97.18
$77.10
$163.71
$5.93B0.82743,626 shs660,520 shs
NovoCure Limited stock logo
NVCR
NovoCure
$17.60
-4.7%
$17.65
$14.17
$34.13
$1.96B0.721.13 million shs876,239 shs
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€25.16
-3.0%
€23.72
€17.12
€26.18
€7.63B0.55277,058 shs278,600 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.00%+0.36%+11.58%+21.86%-10.22%
Glaukos Corporation stock logo
GKOS
Glaukos
0.00%+0.17%+6.51%+15.14%-13.69%
NovoCure Limited stock logo
NVCR
NovoCure
0.00%-0.59%-3.30%+6.67%+4.45%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
0.00%+2.32%+5.49%+15.25%+27.98%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
3.0612 of 5 stars
3.12.00.00.02.11.72.5
Glaukos Corporation stock logo
GKOS
Glaukos
4.3435 of 5 stars
4.41.00.04.42.41.70.6
NovoCure Limited stock logo
NVCR
NovoCure
3.6648 of 5 stars
3.41.00.04.52.51.70.0
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
1.1819 of 5 stars
0.03.00.80.01.70.01.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
2.17
Hold$15.4511.34% Upside
Glaukos Corporation stock logo
GKOS
Glaukos
2.75
Moderate Buy$134.6729.89% Upside
NovoCure Limited stock logo
NVCR
NovoCure
2.71
Moderate Buy$32.4384.25% Upside
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
2.86
Moderate BuyN/AN/A

Current Analyst Ratings Breakdown

Latest NVCR, STVN, GKOS, and BLCO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/9/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$13.00 ➝ $15.00
7/8/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$15.50 ➝ $16.00
7/8/2025
NovoCure Limited stock logo
NVCR
NovoCure
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$30.00
6/30/2025
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
6/27/2025
NovoCure Limited stock logo
NVCR
NovoCure
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$34.00
6/9/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$19.00 ➝ $16.00
5/6/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$18.00 ➝ $12.00
5/6/2025
Glaukos Corporation stock logo
GKOS
Glaukos
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$110.00 ➝ $72.00
5/2/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$20.00 ➝ $15.00
5/2/2025
Glaukos Corporation stock logo
GKOS
Glaukos
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$140.00 ➝ $115.00
5/1/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$14.00 ➝ $13.00
(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$4.79B1.02$1.87 per share7.41$18.57 per share0.75
Glaukos Corporation stock logo
GKOS
Glaukos
$383.48M15.45N/AN/A$13.91 per share7.45
NovoCure Limited stock logo
NVCR
NovoCure
$621.71M3.16N/AN/A$3.33 per share5.29
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€1.19B6.38€0.75 per share33.40€5.02 per share5.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
-$317M-$1.03N/A14.461.56-7.50%2.62%1.28%7/30/2025 (Estimated)
Glaukos Corporation stock logo
GKOS
Glaukos
-$146.37M-$2.37N/AN/AN/A-31.40%-10.66%-8.06%7/30/2025 (Estimated)
NovoCure Limited stock logo
NVCR
NovoCure
-$168.63M-$1.51N/AN/AN/A-26.41%-45.46%-13.34%7/24/2025 (Estimated)
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€127.45M€0.5149.3343.382.4111.14%10.00%6.03%N/A

Latest NVCR, STVN, GKOS, and BLCO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.07N/AN/AN/A$1.25 billionN/A
7/30/2025Q2 2025
Glaukos Corporation stock logo
GKOS
Glaukos
-$0.26N/AN/AN/A$115.49 millionN/A
7/24/2025Q2 2025
NovoCure Limited stock logo
NVCR
NovoCure
-$0.40N/AN/AN/A$153.87 millionN/A
4/30/2025Q1 2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.03-$0.07-$0.10-$0.60$1.15 billion$1.15 billion
4/30/2025Q1 2025
Glaukos Corporation stock logo
GKOS
Glaukos
-$0.33-$0.22+$0.11-$0.32$102.78 million$106.66 million
4/24/2025Q1 2025
NovoCure Limited stock logo
NVCR
NovoCure
-$0.47-$0.31+$0.16-$0.31$147.57 million$154.99 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
N/AN/AN/AN/AN/A
Glaukos Corporation stock logo
GKOS
Glaukos
N/AN/AN/AN/AN/A
NovoCure Limited stock logo
NVCR
NovoCure
N/AN/AN/AN/AN/A
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
N/AN/AN/AN/A1 Years

Latest NVCR, STVN, GKOS, and BLCO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/2/2025
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
annual€0.060.3%6/5/20256/5/20257/17/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.74
1.56
0.96
Glaukos Corporation stock logo
GKOS
Glaukos
0.09
6.49
5.62
NovoCure Limited stock logo
NVCR
NovoCure
0.27
1.47
1.41
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
0.22
1.83
1.26

Institutional Ownership

CompanyInstitutional Ownership
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
11.07%
Glaukos Corporation stock logo
GKOS
Glaukos
99.04%
NovoCure Limited stock logo
NVCR
NovoCure
84.61%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
N/A

Insider Ownership

CompanyInsider Ownership
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.76%
Glaukos Corporation stock logo
GKOS
Glaukos
5.80%
NovoCure Limited stock logo
NVCR
NovoCure
5.52%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
0.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
13,500353.80 million351.12 millionOptionable
Glaukos Corporation stock logo
GKOS
Glaukos
78057.14 million53.83 millionOptionable
NovoCure Limited stock logo
NVCR
NovoCure
1,488111.49 million105.33 millionOptionable
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
5,521302.84 million300.72 millionOptionable

Recent News About These Companies

STVN Stevanato Group S.p.A. - Seeking Alpha
Stevanato Group S.P.A. (IT0005452658.SG)
Stevanato: Recovery Underway, Buy Confirmed

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bausch + Lomb stock logo

Bausch + Lomb NYSE:BLCO

$13.88 -0.32 (-2.25%)
Closing price 07/11/2025 03:59 PM Eastern
Extended Trading
$13.88 -0.01 (-0.04%)
As of 07/11/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

Glaukos stock logo

Glaukos NYSE:GKOS

$103.68 -2.87 (-2.69%)
Closing price 07/11/2025 03:59 PM Eastern
Extended Trading
$103.81 +0.13 (+0.12%)
As of 07/11/2025 05:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

NovoCure stock logo

NovoCure NASDAQ:NVCR

$17.60 -0.86 (-4.66%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$17.98 +0.38 (+2.15%)
As of 07/11/2025 06:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Stevanato Group stock logo

Stevanato Group NYSE:STVN

€25.16 -0.78 (-3.01%)
As of 07/11/2025 03:59 PM Eastern

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.